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ABSTRACT 
Cefopodoxime Proxetil belongs to BCS class IV and used in treatment of upper respiratory tract and urinary 
tract  infections.  Solid  dispersions  (SDs)  are  one  of  the  most  promising  strategies  to  improve  the  solubility, 
dissolution and ultimately oral bioavailability of such poorly water soluble drugs. The main objective of the 
present research was to formulate Cefopodoxime Proxetil solid dispersion employing two methods namely hot 
melt granulation and solvent evaporation method. The PEG 4000 and PEG 6000 were used as carrier in varied 
proportion (1:1, 1:2, 1:3 and 1:4 w/w). Results of FT-IR spectra revealed no potential chemical incompatibility 
between drug and excipients. Enhancement in the percent drug released and dissolution rate was observed in 
SD of PEG 6000 as to PEG 4000 and pure drug. Drug release kinetics studies revealed that the drug release from 
the formulations followed non-fickian diffusion and the best fitted model for drug release for Korsmeyer Peppas 
Model. No sharp peaks were observed in both solid dispersions (comprising PEG 4000 & PEG 6000) in PXRD 
spectra revealing the formation of amorphous product. Similar results were observed in DSC studies indicating 
disappearance of sharp fusion endothermic peak i.e. conversion of crystalline form into amorphous form. These 
results were further supported by SEM studies showing disappearance of crystal habit in these formulations. 
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INTRODUCTION 
Solubility is one of the important parameters to deliver 
the  oral  dosage  forms  to  a  target  site  with  desired 
concentration  in  systemic  circulation  for  achieving 
required pharmacological response.  [1] But, more than 
90% of drugs developed or approved in pharmaceutical 
industry  have  poor  solubility,  poor  permeability,  or 
both. [2-4] Such poorly water-soluble drugs often require 
high doses in order to reach with optimum therapeutic 
plasma concentrations at target site after oral  
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administration. 
Cefopodoxime  Proxetil  (CP)  is  an  orally  absorbed, 
broad  spectrum,  third  generation  cephalosporin  ester 
implicated  in  treatment  of  skin  infections,  upper 
respiratory tract and urinary tract infections. It belongs 
to  BCS  class  IV  (i.e.  low  solubility  and  low 
permeability).    When  administered  orally,  it  shows 
poor  gastrointestinal  absorption  because  of  its  low 
dissolution  rate  in  aqueous  media  and  poor 
permeability. [3] However, the major challenge with the 
design  of  oral  dosage  forms  lies  with  their  poor 
bioavailability.  Increased  efforts  is  been  done  for  the 
development  of  pharmaceutical  formulations  with 
enhanced oral bioavailability of API by enhancing its 
solubility as well permeability. Gupta et al. / Fabrication and Characterization of Cefopodoxime Proxetil Solid Dispersion…..…… 
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There are numerous approaches available and reported 
in  literature  to  enhance  the  solubility  of  such  poorly 
water-soluble drugs like particle-size reduction which 
includes  micro  sizing  and  nanosizing,  salt  formation, 
solubilization, and complexation with β cyclodextrins. 
[5]  All  these  methods  suffer  from  one  or  the  other 
drawbacks.  The  formulation  of  drugs  having  low 
aqueous solubility using solid dispersion method has 
been  an  active  area  of  research  to  overcome  the 
problem associated with above mentioned methods. [6] 
Solid  dispersion  refers  to  a  group  of  solid  products 
consisting  of  at  least  two  different  components, 
generally  a  hydrophilic  matrix  and  a  hydrophobic 
drug.  [7]  The  drug  can  be  dispersed  molecularly,  in 
amorphous particles (clusters) or in crystalline particles 
by various methods such as melting method, hot melt 
granulation,  hot  melt  extrusion  and  solvent 
evaporation  method.  [8]  The  main  objective  of  the 
present investigation was to enhance the solubility and 
dissolution  rate  of  Cefopodoxime  Proxetil  by 
formulating its solid dispersions into a oral dispersible 
tablets. [9] 
In the present work study the solid dispersion of CP 
was formulated by employing two methods namely hot 
melt  granulation  and  solvent  evaporation  method.  
Solid  dispersions  of  Cefopodoxime  Proxetil  were 
developed with different water soluble carriers i.e. PEG 
4000 and PEG 6000 in the proportion of 1:1, 1:2, 1:3 and 
1:4 w/w. PEG is freely soluble in water and releases the 
entrapped drug as fine colloidal particles in presence of 
aqueous media. [10] 
 
Table 1: Formulation codes of CP solid dispersions with different 
carriers  prepared  in  varying  proportions  employing  different 
methods. 
Carrier  Ratios  
(w/w) 
Formulation prepared by different methods 
Hot melt granulation  Solvent evaporation 
PEG 
4000 
1:1  CPEhg1:1  CPEse1:1 
1:2  CPEhg1:2  CPEse1:2 
1:3  CPEhg1:3  CPEse1:3 
1:4  CPEhg1:4  CPEse1:4 
PEG 
6000 
1:1  CPGhg1:1  CPGse1:1 
1:2  CPGhg1:2  CPGse1:2 
1:3  CPGhg1:3  CPGse1:3 
1:4  CPGhg1:4  CPGse1:4 
 
MATERIALS AND METHODS 
Preparation of Physical mixtures 
Drug  and  carriers  (PEG  4000  and  PEG  6000)  are 
accurately weighed and mixed in different ratios (1:1, 
1:2, 1:3, 1:4 w/w) are thoroughly blended  in pestle and 
mortar for 5 min., and then carefully sieved through 22 
mesh sized sieve. The prepared mixtures were kept in 
desiccators before further study. [11]  
Preparation  of  Solid  Dispersions:  Solid  dispersions 
were  formulated  using  various  water-soluble  carriers 
viz.  PEG  4000  and  PEG  6000  in  varying  proportions 
(1:1, 1:2, 1:3, 1:4 w/w) by solvent evaporation and hot 
melt granulation method. [12] 
Solvent  Evaporation  Method:  Drug  was  accurately 
weighed  and  dissolved  in  20  ml  of  methanol  using 
magnetic  stirrer  and  after  complete  solubilization  in 
methanol,  the  carrier  (PEG)  was  added.  The  solution 
was heated to 40°C on a hot plate to get a clear solution. 
Then the solvent was allowed to evaporate in hot air 
oven  at  40°C.  The  process  of  evaporation  was  opted 
until  the  constant  weight  was  obtained.  Solid 
dispersions  prepared  were  crushed,  pulverized  and 
sifted through mesh no. 22 to get the uniform particle 
size  of  solid  dispersion.  Different  code  names  were 
given to different ratios (Table 1). [13] 
Hot  Melt  Granulation:  Each  carrier  (PEG  4000  and 
PEG  6000)  were  accurately  weighed  and  melted  in  a 
china  dish  on  a  water  bath  maintained  at  their 
respective melting temperatures. The CP was added to 
the molten carriers and mixed thoroughly with a glass 
rod  for  10  min.  The  mixture  was  cooled  rapidly  by 
placing the china dish in an ice bath to get uniformly 
solidified  dispersion.  The  prepared  solid  dispersion 
was sieved and stored in vacuum desiccator. [14] 
Evaluation of Prepared Solid Dispersions 
Drug  Excipient  compatibility  Studies  by  FTIR 
Spectroscopy 
To check any interaction between the drug, carriers and 
excipients,  FTIR  studies  was  carried  out  on  drug 
(Cefopodoxime Proxetil), physical mixtures as well as 
on treated sample. Figure 1 shows the FTIR spectra of 
CP, physical mixtures and treated samples of drug with 
different  carriers  viz  PEG  4000  and  PEG  6000  in  the 
proportion of 1:1 w/w. 
Determination of Percent Yield: The percent yield was 
calculated using the equation 1. 
 
Determination of Percent Drug Content: Drug content 
was  calculated  by  dissolving  solid  Dispersion 
containing drug equivalent to 10 mg of Cefopodoxime 
Proxetil in 10 ml of methanol, filtering and analyzing at 
235 nm by UV spectrophotometer. [15] The percent drug 
content was calculated using the equation 2. 
 
In  vitro  Dissolution  studies:  The  best  method  was 
selected out of three methods applied to prepare solid 
dispersion on the basis of percent drug release. On all 
the  selected  formulations,  dissolution  studies  were 
performed using USP apparatus type II (equipped with 
paddle). SDs powder equivalent to  100 mg drug was 
put in 900 ml of serum gastric fluid 0.1 N HCl without 
enzyme  as  dissolution  media.  The  rotation  speed  of 
paddle  was  set  at  75  rpm  and  the  temperature 
maintained at 37 +/- 0.5°C. In all experiments, 10 ml of 
dissolution sample was withdrawn at 5, 10, 15, 20, 30, 
45, 60 minutes and replaced with an equal volume of 
fresh  medium  to  maintain  the  sink  conditions.  The 
filtered  samples  were  analyzed  by  UV 
spectrophotometer  at  235  nm.  Appropriate  correction 
for drug and volume losses during each sampling was 
applied by using equation 3. Gupta et al. / Fabrication and Characterization of Cefopodoxime Proxetil Solid Dispersion…..…… 
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                     (3) 
Where, Ci is the corrected absorbance of ith observation, 
Ai is the observed specific absorbance, Vs is the sample 
volume,  and  Vt  is  the  total  volume  of  dissolution 
medium. 
Determination  of  Dissolution  Parameters:  Percent 
released at three time points (PD10, PD30 and PD60) was 
calculated  from  the  dissolution  data.  
Kinetic  Modeling:  In  vitro  drug  release  data  of 
formulation amongst each carrier which showed ceiling 
aptness  in  dissolution  characteristics  was  fitted  to 
various release kinetic models (Table 2) viz Zero order, 
First-order,  Higuchi,  Hixson-Crowell,  Korsmeyer–
Peppas model. 
  
Table 2: Representative equations of release kinetic models 
Kinetics    Equation 
Zero order  :  Mo - Mt = kot 
First order  :  ln(Mo/Mt) = k1t 
Korsmeyer Peppas  :  Mt/  = ktn 
Higuchi  :  K  
Hixson Crowell  :  (Wo)1/3 – (Wt)1/3 = K1/3t 
Where, Mo, Mt and   correspond to the drug amount 
taken  at  time  equal  to  zero,  dissolved  at  a  particular 
time, t, and at infinite time, respectively. The terms, Wo 
and Wt refer to the weight of the drug taken initially 
and at time t, respectively. Various other terms viz. ko, 
k1, k, K and k1/3 refer to the release kinetic constants 
obtained  from  the  linear  curves  of  zero-order,  first-
order,  Korsemeyer–Peppas,  Higuchi  model  and 
Hixson-Crowell cube root model respectively. 
Differential Scanning Calorimetry (DSC) Studies 
DSC  thermograms  were  obtained  on  DSC,  Q20,  TA 
Instruments-Waters  LLC,  USA.  The  calorimeter  was 
calibrated  for  temperature  and  heat  flow  accuracy 
using the melting of pure indium (mp 156.6°C and ∆H 
of 25.45 Jg-1). A mass between 2-8 mg was taken into 
the aluminium pan, covered with lid and sealed. DSC 
curves were obtained under a nitrogen purge of 50 ml 
per minute at a heating rate of 10°C per minute with 
the temperature range from 50-350°C. 
Powder X-Ray Diffraction (PXRD) Studies 
The  PXRD  pattern  was  recorded  using  high  power 
powder  x-ray  diffractometer  (XPERT-PRO, 
PANalytical,  Netherlands,  Holand)  with  Cu  as  tube 
anode.  The  diffractograms  were  recorded  under 
following  conditions:  voltage  40  kV,  35  mA,  angular 
range  5  and  fixed  divergence  slit.  Care  was  taken  to 
avoid  crystal  changes  during  sample  preparation. 
Approximately 200 mg of samples were loaded into the 
sample holder, taking care not to introduce preferred 
orientation of the crystals. 
Scanning Electron Microscopy (SEM) 
The  shape  and  surface  characteristics  of  the  ground 
mixtures were studied by SEM. The SEM analysis was 
carried  out  using  a  scanning  electron  microscope 
(Hitachi  S-3600  N,  Japan).  Prior  to  examination, 
samples were mounted on an aluminum stub using a 
double  sided  adhesive  tape  and  then  making  it 
electrically conductive by coating with a thin layer of 
gold (approximately 20 nm) in vacuum. The scanning 
electron  microscope  was  operated  at  an  acceleration 
voltage of 15 kV. 
 
RESULTS AND DISCUSSION 
Percent Yield  
Percent  yield  and  drug  content  for  solid  dispersion 
formulations  containing  PEG  4000  were  calculated 
using formula given in equation 2. Calculated percent 
yield  of  eight  formulations  of  PEG  4000  prepared  by 
HG  and  SE  lies  in  range  of  92.3  to  97.8  %  w/w. 
Whereas  the  percent  yield  of  PEG  6000  formulations 
prepared by HG and SE methods varied between 93.7 
to 98.3%.  
Out of all the formulations CPGse1:4 containing PEG 
6000 prepared by SE have shown highest yield (98.3 %) 
whereas  CPEhg1:1  containing  PEG  4000  prepared  by 
HG have produced minimum yield (93.7%)  
Drug Content    
The  drug  content  in  the  SD  formulations  containing 
PEG 4000 as well as PEG 6000 is above than 86 to 96.8% 
as shown in Table 3. The drug content was found to be 
minimum  (89%)  for  CPEhg1:1  (PEG  4000)  whereas 
CPGse1:4% (PEG 6000) have shown maximum (96.8%) 
drug  content.  PEG  6000  containing  formulations 
showed  better  results  than  PEG  4000  formulations 
because of  its high molecular weight which leads to 
formation  of  fine  microcrystal’s  and  absence  of  drug 
clusters. 
In vitro Release Studies of Formulations Containing 
PEG 4000 
The  best  method  was  selected  out  of  three  methods 
applied  to  prepare  solid  dispersion  on  the  basis  of 
percent  drug  release.  On  all  the  formulations, 
dissolution studies were carried out in SGF 0.1 N HCl 
without enzyme. 
Table 3: Percent yield and drug content of solid dispersions having PEG 4000 and PEG 6000 
S. 
No. 
Formulation using 
PEG 4000 
Percent yield 
(w/w) (%) 
Drug content 
(w/w) (%) 
Formulation using 
PEG 6000 
Percent yield 
(w/w) (%) 
Drug content 
w/w (%) 
1.  CPEhg1:1  92.3  89.0  CPGhg1:1  93.7  93.4 
2.  CPEhg1:2  93.5  91.4  CPGhg1:2  94.9  89.3 
3.  CPEhg1:3  96.8  92.6  CPGhg1:3  95.8  92.0 
4.  CPEhg1:4  97.3  94.8  CPGhg1:4  96.7  95.1 
5.  CPEse1:1  94.07  93.0  CPGse1:1  95.3  94.3 
6.  CPEse1:2  95.8  95.7  CPGse1:2  96.4  96.2 
7.  CPEse1:3  96.2  96.5  CPGse1:3  97.7  96.6 
8.  CPEse1:4  97.8.  96.8  CPGse1:4  98.3  98.8 Gupta et al. / Fabrication and Characterization of Cefopodoxime Proxetil Solid Dispersion…..…… 
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Dissolution data of physical mixtures of drug with PEG 
4000 in different proportions indicates the existence of 
ascending trend in both maximum percent release and 
dissolution  rate  i.e.,  CPEpm1:1  <  CPEpm1:2  < 
CPEpm1:3  <  CPEpm1:4.    Maximum  percent  released 
and  overall  dissolution  rate  of  CPEpm1:4  were 
observed to be highest (45.32%). 
In vitro Release Studies of Formulations Containing 
PEG 6000 
In vitro drug release data concluded that as the increase 
percent  release  due  to  increased  wettability  and 
decreased surface tension of drug. 
From  graph  (figure  1a),  it  is  clear  that  dissolution 
profile  of  CP  in  PEG  4000  PM  formulations  slowly 
increased with time but after 45 min dissolution profile 
becomes constant. Results of dissolution studies of SDs 
indicated  the  existence  of  ascending  trend  in 
dissolution  profile  i.e.  1:1  <  1:2  <  1:3  <  1:4  w/w 
proportion  of  carrier.  Increased  solubility  of  CP  was 
due to encapsulation of drug inside the diffusion layers 
of PEG. It followed the diffusion controlled release of 
the drug from the polymer matrix. The improvement of 
dissolution  profile  may  be  due  to  strong  hydrophilic 
character.  Formulations  prepared  by  hot  melt 
granulation  as  well  as    solvent  evaporation  methods 
revealed  increased  rate  of  dissolution  with  increased 
level of carrier in formulations in the order of  1:1 <1:2 
<1:3 <1:4 w/w.  
 
Fig. 1a: In vitro release graph of formulations containing PEG 6000 
 
Fig. 1b: In vitro release graph of formulations containing PEG 6000 
Similar  results  were  found  with  solid  dispersion 
formulations containing PEG 6000 as shown in figure 1 
b. However, formulations prepared with 1:1 w/w PEG 
6000 showed minimum release as compared with 1:2, 
1:3 and 1:4 w/w carrier formulations. The order of drug 
release was found to be CP<PM<SD (SDhg<SDse). 
Dissolution  Parameters  of  Formulations  Containing 
PEG 4000 and PEG 6000 
For  each  formulation  of  PEG  4000,  dissolution 
parameters (PD10, PD30, and PD60) were calculated and 
presented  graphically  (Figure  2a).  In  case  of  physical 
mixture,  in-vitro  drug  release  increases  with  time  as 
well  as  with  increase  in  concentration  of  carriers  as 
compared to drug. For each formulation of PEG 6000, 
dissolution  parameters  (PD10,  PD30,  and  PD60)  was 
calculated and presented graphically. 
 
Fig. 2a: Dissolution parameters of Cefpodoxime proxetil and solid 
dispersion of drug with PEG 4000 formulations in different ratios 
 
Fig.  2b:  Dissolution  parameters  of  Cefdoxime  proxetil  and  solid 
dispersion containing PEG 6000 formulations in different ratios. 
The  solubility  and  dissolution  studies  showed 
improved  solubility  of  CP  through  solid  dispersion 
with PEG 6000 than with PEG 4000, due to the reason 
that  the  high  molecular  weight  of  PEG  6000  which 
leads to formed fine microcrystal in formulation and 
absence of drug clusters. The formulation containing 
CPGse1:4  (PEG6000)  was  found  to  be  better  as 
compared  with  other  formula tion  CPGhg1:4  (Figure 
2b). 
Kinetic  Modelling  of  PEG  6000  Formulation 
(CPGse1:4) with Best Dissolution Characteristics 
Kinetic models (Zero order model, First order model, 
Korsmeyer Peppas model, Higuchi model and Hixson Gupta et al. / Fabrication and Characterization of Cefopodoxime Proxetil Solid Dispersion…..…… 
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Crowell  model)  was  applied  to  best  formulation 
(CPGse1:4).  
 
Fig. 3 (a): Higuchi model 
 
Fig. 3 (b): Korsmeyer Peppas model 
 
Table 4: Regression parameters of CPGse1:4 obtained after fitting 
the data to various release models 
Regression 
parameters 
Zero 
order 
First 
order 
Korsmeyer 
peppas 
model 
Higuchi 
model 
Hixson 
crowell 
model 
Slope  0.975  0.008  0.607  10.31  0.023 
R2  0.897  0.945  0.973  0.965  0.933 
 
Table 4 enlists the regression parameters obtained after 
fitting  various  release  kinetic  models  to  the  in-vitro 
dissolution data of CPEse1:4. The value of regression 
coefficient indicated that the goodness of fit for various 
models followed in the order of Korsmeyer Peppas > 
Higuchi > First order > Hixson Crowell > Zero order. 
By and large, the Korsmeyer Peppas model described 
drug  release  kinetics  in  the  most  befitting  manner. 
Value  of  the  slope  of  CPGse1:4  were  0.607  which 
depicted  that  it  followed  the  non-fickian  diffusion  as 
possible mechanism of drug release. 
On  comparing  results  of  all  the  best  formulations 
containing PEG 4000 and PEG 6000, it was concluded 
that  CPGse1:4  have  shown  highest  percent  release  of 
drug from polymer matrix and were chosen for further 
study. 
Powder X-ray Diffraction (PXRD) Studies 
The powder X-ray diffraction studies were carried out 
on  given  powder  of  samples.  PXRD  pattern  of  CP 
showed  characteristics  diffraction  peaks  at  (2θ)  9.63o, 
11.24o,  15.90o,  16.889o,  17.56o,  18.04o,  19.74o,  22.84o, 
28.68o,  33.51o,  35.17o,  and  38.73oOn  comparing  the 
position and the relative intensities of the major peaks 
of SDs prepared by using PEG 4000 and PEG 6000 with 
those  of  pure  components,  a  distinct  difference  was 
visible  which  confirms  the  differences  in  the 
crystallinity  of  the  different  forms  indicating  its 
crystalline nature. Moreover, much reduced number of 
signals,  with  remarkably  lowered  intensity  was 
observed  in  both  SDs  as  shown  in  figure  5.  This 
suggested  that  reduced  crystallinity  attributed  to  the 
reciprocal  interactions  between  host  and  the  guest  in 
the  solid  state.  Besides  this,  decrease  in  particle  size 
during formulation is also responsible for the decrease 
in  peak  intensities.  The  increased  amorphous  nature 
among SDs having PEG 4000 and PEG 6000 indicated 
the entrapment of drug inside the polymer. 
 
 
Fig. 4: Dissolution profile best formulations of PEG 4000 and PEG 
6000 
 
Fig.  5:  X-ray  diffraction  pattern  of  (a)  Cefpodoxime  proxetil  (b) 
Optimized  formulation  with  PEG  4000  (c)  and  optimized 
formulation with PEG 6000 Gupta et al. / Fabrication and Characterization of Cefopodoxime Proxetil Solid Dispersion…..…… 
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Differential Scanning Calorimetry (DSC) Studies 
The  existence  of  an  interaction  as  well  as  detailed 
information  about  change  in  both  the  physical  and 
energetic  properties  between  the  drug  and  polymers 
can  be  obtained  by  thermal  analysis.  DSC,  a  thermal 
analysis technique of choice is frequently used because 
of its ability to provide detailed information about both 
the  physical  and  energetic  properties  of  a  substance 
when  the  guest  molecules  are  entrapped  inside  the 
polymer  matrix,  their  melting  and  boiling  points 
usually  shift  to  a  different  temperature  or  disappear. 
The  DSC  curve  of  CP  showed  a  characteristic  fusion 
endothermic  peak  at  101.13°C  corresponding  to  its 
melting point. DSC thermogram of the pure drug was 
compared with that of the complexes which revealed 
important  information  about  the  complex  formation. 
The  disappearance  of  an  endothermic  peak  in  SDs 
(Figure 6) may be attributed to inclusion of drug in the 
polymer and formation of amorphous form. 
Scanning electron microscopy (SEM) 
SDs of best formulations (PEG-6000) was subjected to 
SEM studies which revealed a change in their surface 
characteristics (shape and appearance). The commercial 
sample  (CP)  was  highly  crystalline  material  and 
characterized by its needle shaped crystals whereas no 
characteristic  shape  of  crystals  was  observed  in  solid 
dispersion  having  PEG  6000  as  shown  in  Figure  7 
which  inferred  that  crystallinity  of  drug  had  been 
reduced or might be changed to amorphous state.  
Infrared Spectroscopy 
FTIR spectrum of CP showed a peaks at 3743 cm-1, 3311 
cm-1, 3308 cm-1, 2998 cm-1, 2939 cm-1, 2302 cm-1, 1754 cm-
1, 1678 cm-1, 1534 cm-1& 1273 cm-1 were due to amide N-
H  stretch,  alcohol/phenol  O-H  Stretch,  alkynyl  C=C 
Stretch,  ketone  C=O  Stretch,    amide  C=O  Stretch, 
aromatic  C=C  Bending,  C-H  stretching  respectively. 
The characteristic peaks of the drug in the IR spectrum 
were  retained  in  the  treated  sample  when  compared 
with physical mixture which indicated that there is no 
incompatibility between drug, carriers and excipients. 
It was observed that  no significant  shift in  the peaks 
corresponding  to  the  drug,  which  is  an  indicative  of 
compatibility between the drug, carriers and excipients 
as shown in figure 8. 
Solid  dispersions  formulations  prepared  using  PEG 
6000 as carrier followed the same trend of drug release 
as  in  SDs  with  PEG  4000.  2.5  times  increase  in  the 
percent  drug  released  and  dissolution  rate  was 
observed (CPGse1:4) as compared to pure drug. 
Out  of  two  methods  used  for  preparing  SDS  using 
different ratios, SE was observed to be best method and 
CPGse1:4 have shown highest percent drug release. 
 
 
Fig. 6: DSC thermogram of Cefopodoxime Proxetil optimized formulation with PEG 6000 
 
Fig. 7: Scanning electron photomicrographs of CP and optimized solid dispersion with PEG 6000 Gupta et al. / Fabrication and Characterization of Cefopodoxime Proxetil Solid Dispersion…..…… 
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Fig. 8: FTIR Spectra of: (A) Drug (CP) (B) Physical Mixture of PEG 4000 with drug and excipients (C) Physical Mixture of PEG 6000 with 
drug and excipients (D) Treated sample containing PEG 4000 with drug and excipients, (C) Treated Sample containing PEG 6000with drug 
and excipients 
 
This may be due to increased amount of water soluble 
carriers.  The  value  of  slope  (0.607)  indicated  that  it 
follows  non-fickian  diffusion  and  a  result  of  kinetics 
release was best fitted in Korsemeyer Peppas model. 
Finally, the selected SDs were further characterized by 
PXRD, DSC and SEM. PXRD of formulations (with PEG 
6000) showed much reduced intensities in characteristic 
peaks  of  drug  revealing  that  drug  was  encapsulated 
inside  the  carrier.  The  DSC  of  SDs  with  PEG  6000 
showed  the  absence  of  melting  endotherm  depicting 
that  drug  was  solubilized  in  polymeric  matrix  which 
further  inferred  the  change  of  crystallinity  nature  of 
drug into an amorphous form. The SEM photographs 
of CP indicated the change of topography from needle 
shape  to  no  characteristic  shape  of  crystals  inferring 
that crystallinity of drug had been reduced or changed 
to amorphous form. 
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